REG - Theracryf PLC - AGM Statement

TheracryfAnnouncement

09/07/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250709:nRSI2606Qa&default-theme=true

RNS Number : 2606Q  Theracryf PLC  09 July 2025

 

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

 

AGM Statement

 

Alderley Park, 9 July 2025 - TheraCryf plc (AIM: TCF), the clinical stage
drug development company focussing on brain disorders, will be holding its
Annual General Meeting at 2:30pm BST today at The Royal Society of Medicine, 1
Wimpole St, London, W1G 0AE.

 

At the AGM, TheraCryf's Chair, Dr Alastair Smith; CEO, Dr Huw Jones; CFO, Toni
Haenninen and CBO, Dr Helen Kuhlman will give the following operational update
to shareholders:

 

Ox-1

Lead asset Ox-1, TheraCryf's orexin 1 antagonist in addictive behaviours,
continues to make good progress following the fundraising in March of this
year to fund the programme to clinical readiness. Having appointed leading
contract research and manufacturing organisation, Pharmaron UK, as  partner,
their team are currently working on optimising the synthesis of Ox-1 in order
to scale up to produce the kilogram quantities required for regulatory
standard toxicology work and later, clinical studies.

 

The Ox-1 molecule has been shown to be highly stable at room temperature. An
archive sample produced by Chronos Therapeutics Ltd in 2020, tested at
Pharmaron, was found to have greater than 99% purity. This potential for
long-term stability, which will be confirmed with additional stability testing
of the newly produced material, will be an important factor in achieving
optimal commercial potential. The chemistry and biology work are progressing
well with testing underway to understand further characteristics of Ox-1's
synthesis and activity.

 

Additional in vitro testing indicates that Ox-1 is well handled in cells from
a new, fourth species, which will be essential to confirm its toxicology
profile, a key enabling study before eventual permission to administer the
agent to man.

 

SFX-01

The company's legacy SFX-01 programme also continues to progress with the
grant-funded Glioblastoma (GBM) project at the Erasmus Medical Centre in the
Netherlands confirming that drug from SFX-01 crosses the blood-brain barrier
in in vivo experiments, essential for GBM brain tumour treatment.

 

An academic collaboration in the USA on colorectal cancer has also reported
data showing that Nrf2, a known molecular target, is up-regulated by SFX-01
only in diseased colon cancer models and not where the disease is absent.

 

Further, collaborating teams from Queen Mary University of London, Barts
Hospital, Imperial College London, UCL, University of Oxford and University of
Leicester have had a scientific paper on the effects of SFX-01 on another
molecular target, SHP-2, accepted by a peer-reviewed journal which will be
published imminently.

 

Dr Huw Jones, CEO of TheraCryf commented:

"We are pleased with how our Ox-1 programme is developing on-time and to-plan
as we complete the final steps for readiness for human trials. Our commercial
and academic collaborations are continuing to generate insightful data. We
would like to thank our shareholders for their continued support as we unlock
value from our assets."

 

-Ends-

Enquiries

 TheraCryf plc                                       +44 (0)1625 315 090

 Dr Huw Jones, CEO                                   enquiries@theracryf.com

 Toni Hänninen, CFO

 Dr Helen Kuhlman, CBO

 Singer Capital Markets (NOMAD & Joint Broker)       +44 (0)20 7496 3000
 Phil Davies / Oliver Platts / Patrick Weaver

 Turner Pope Investments (Joint Broker)              +44 (0)20 3657 0050

 James Pope / Andy Thacker

 Vigo Consulting                                     +44 (0)20 7390 0230

 Rozi Morris                                         theracryf@vigoconsulting.com

About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on brain
disorders. The Company has a broad clinical and preclinical pipeline in
indications including addiction, anxiety, fatigue, narcolepsy, glioblastoma*
and neurodevelopmental disorders [*orphan indication].

 

The Company's strategy is to generate compelling data sets to preclinical
and/or clinical proof of concept and partner its clinical programmes with
mid-size to large pharma for larger trials and commercialisation. It also has
a number of industry partnerships with companies, including Stalicla SA, in
neurodevelopmental disorders.  The Company has sourced know-how for
programmes from companies such as Shire (now Takeda).

 

TheraCryf has worked with and has ongoing collaborations with major
universities and hospitals such as the University of Manchester, La Sapienza
(Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College
London and the University of Michigan.

 

The Company has its headquarters and registered office at Alderley
Park, Cheshire. It is quoted on AIM in London and trades under the
ticker symbol TCF. 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGMDBGDRIBGDGUI